Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Front-Line PET/CT-2 Response-Adapted Brentuximab Vedotin and Nivolumab Incorporated and Radiation-Free Management of Early Stage Classical Hodgkin Lymphoma (cHL)

NCT03712202 is registered in ClinicalTrials.gov with City of Hope Medical Center as lead sponsor.

NCT NCT03712202
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03712202 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Front-Line PET/CT-2 Response-Adapted Brentuximab Vedotin and Nivolumab Incorporated and Radiation-Free Management of Early Stage Classical Hodgkin Lymphoma (cHL)
Lead sponsor
City of Hope Medical Center
Phase
Phase 2
Overall status
Active, not recruiting
Start date
November 28, 2018
Completion date
December 23, 2024
Enrollment
155 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

ann arbor stage i hodgkin lymphoma, ann arbor stage i lymphocyte-depleted classic hl, ann arbor stage i mixed cellularity classic hodgkin lymphoma, ann arbor stage i nodular sclerosis classic hodgkin lymphoma, ann arbor stage ia hodgkin lymphoma, ann arbor stage ib hodgkin lymphoma, ann arbor stage ii hodgkin lymphoma, ann arbor stage ii lymphocyte-depleted classic hl, ann arbor stage ii mixed cellularity classic hl, ann arbor stage ii nodular sclerosis classic hl, ann arbor stage iia hodgkin lymphoma, ann arbor stage iib hodgkin lymphoma, classic hodgkin lymphoma, lymphocyte-rich classic hodgkin lymphoma